Histone deacetylase inhibition alters dendritic cells to assume a tolerogenic phenotype and ameliorates arthritis in SKG mice

Arthritis Res Ther. 2011 May 18;13(3):R77. doi: 10.1186/ar3339.

Abstract

Introduction: The purpose of this study was to elucidate the effects of histone deacetylase inhibition on the phenotype and function of dendritic cells and on arthritis in SKG mice.

Methods: Arthritis was induced in SKG mice by zymosan A injection. Trichostatin A, a histone deacetylase inhibitor, was administered and its effects on arthritis were evaluated by joint swelling and histological evaluation. Interleukin-17 production in lymph node cells was determined by an enzyme-linked immunosorbent assay (ELISA). Foxp3 expression in lymph node cells and the phenotypes of splenic dendritic cells were examined by fluorescence-activated cell sorting (FACS). Bone marrow-derived dendritic cells (BM-DC) were generated with granulocyte macrophage colony-stimulating factor. The effects of trichostatin A on cell surface molecules, cytokine production, indoleamine 2,3-dioxygenase (IDO) expression and T cell stimulatory capacity were examined by FACS, ELISA, quantitative real-time polymerase chain reaction and Western blot, and the allo-mixed lymphocyte reaction, respectively.

Results: Trichostatin A, when administered before the onset of arthritis, prevented SKG mice from getting arthritis. Trichostatin A treatment also showed therapeutic effects on arthritis in SKG mice, when it was administered after the onset of arthritis. Trichostatin A treatment reduced Th17 cells and induced regulatory T cells in lymph node, and also decreased co-stimulatory molecule expression on splenic dendritic cells in vivo. In vitro, trichostatin A markedly suppressed zymosan A-induced interleukin-12 and interleukin-6 production by BM-DC and up-regulated IDO expression at mRNA and protein levels. Trichostatin A-treated BM-DC also showed less T cell stimulatory capacity.

Conclusions: Histone deacetylase inhibition changes dendritic cells to a tolerogenic phenotype and ameliorates arthritis in SKG mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arthritis, Experimental* / chemically induced
  • Arthritis, Experimental* / drug therapy
  • Arthritis, Experimental* / immunology
  • B7-1 Antigen / immunology
  • B7-1 Antigen / metabolism
  • B7-2 Antigen / immunology
  • B7-2 Antigen / metabolism
  • CD40 Antigens / immunology
  • CD40 Antigens / metabolism
  • Cell Division / drug effects
  • Cell Division / immunology
  • Dendritic Cells / cytology
  • Dendritic Cells / enzymology*
  • Dendritic Cells / immunology
  • Female
  • Forkhead Transcription Factors / immunology
  • Forkhead Transcription Factors / metabolism
  • Histocompatibility Antigens Class II / immunology
  • Histocompatibility Antigens Class II / metabolism
  • Histone Deacetylase Inhibitors / pharmacology*
  • Histone Deacetylases / immunology
  • Histone Deacetylases / metabolism
  • Hydroxamic Acids / pharmacology*
  • Immune Tolerance / drug effects*
  • Immune Tolerance / immunology
  • Immunophenotyping
  • Indoleamine-Pyrrole 2,3,-Dioxygenase / immunology
  • Indoleamine-Pyrrole 2,3,-Dioxygenase / metabolism
  • Interleukin-17 / immunology
  • Interleukin-17 / metabolism
  • Lymph Nodes / cytology
  • Lymph Nodes / immunology
  • Mice
  • Mice, Inbred C57BL
  • Species Specificity
  • Spleen / cytology
  • Spleen / immunology
  • T-Lymphocytes / cytology
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology
  • Zymosan / toxicity

Substances

  • B7-1 Antigen
  • B7-2 Antigen
  • CD40 Antigens
  • Cd86 protein, mouse
  • Forkhead Transcription Factors
  • Foxp3 protein, mouse
  • Histocompatibility Antigens Class II
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Indoleamine-Pyrrole 2,3,-Dioxygenase
  • Interleukin-17
  • trichostatin A
  • Zymosan
  • Histone Deacetylases